This company has been marked as potentially delisted and may not be actively trading. NASDAQ:EUCR Eucrates Biomedical Acquisition (EUCR) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Eucrates Biomedical Acquisition Stock (NASDAQ:EUCR) 30 days 90 days 365 days Advanced Chart Get EUCR alerts:Sign Up Key Stats Today's Range$10.02▼$10.0450-Day Range$10.04▼$10.2552-Week Range$9.87▼$10.25Volume12,700 shsAverage Volume2,287 shsMarket Capitalization$42.27 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Eucrates Biomedical Acquisition Corp. does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It focuses to identify and acquire a business in the biomedical or healthcare-related industries in North America and Europe. The company was incorporated in 2020 and is based in New York, New York. Read More Receive EUCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eucrates Biomedical Acquisition and its competitors with MarketBeat's FREE daily newsletter. Email Address EUCR Stock News HeadlinesZymergen nears final chapter with Bankruptcy Court settlementMay 17, 2024 | bizjournals.comPsyence Biomedical Finalizes Strategic Merger AgreementFebruary 1, 2024 | msn.comThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 trillion vault of untapped American wealth. Former CIA advisor Jim Rickards calls it the “Old Testament Wealth Code” — and says it could transform your financial future. He’s revealing everything in a new presentation. | Paradigm Press (Ad)What's Going On With Emergent Biosolutions Stock?November 28, 2023 | msn.comMineralys Therapeutics, Inc.: Mineralys Therapeutics Expands its Board of Directors with Appointments of Glenn Sblendorio and Daphne KarydasSeptember 15, 2023 | finanznachrichten.de8-K: Eucrates Biomedical Acquisition Corp.February 18, 2023 | marketwatch.comOcean Biomedical stock falls 26%, down 60% since SPAC mergerFebruary 18, 2023 | msn.comOcean Biomedical Debuts on Nasdaq, Shares Trading 11% LowerFebruary 16, 2023 | marketwatch.comSee More Headlines EUCR Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Eucrates Biomedical Acquisition own? Based on aggregate information from My MarketBeat watchlists, some other companies that Eucrates Biomedical Acquisition investors own include Sprott Focus Trust (FUND), Meta Platforms (META), ETFMG Alternative Harvest ETF (MJX), New Zealand Energy (NZ), Strathcona Resources (SCR) and Shopify (SHOP). Company Calendar Today8/21/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry Holding & other investment offices Sub-IndustryN/A Current SymbolNASDAQ:EUCR CIK1822929 WebN/A Phone212-710-5220FaxN/AEmployees4Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$2.42 million Net MarginsN/A Pretax MarginN/A Return on Equity-62.82% Return on Assets2.95% Debt Debt-to-Equity RatioN/A Current Ratio2.03 Quick Ratio2.03 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash Flow$0.81 per share Price / Cash Flow12.36 Book Value($1.25) per share Price / Book-8.03Miscellaneous Outstanding Shares4,210,000Free Float3,386,000Market Cap$42.27 million OptionableNot Optionable Beta-0.07 Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NASDAQ:EUCR) was last updated on 8/22/2025 by MarketBeat.com Staff From Our Partners[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredUS attacks China, September 30?The White House just ordered more than 400 government agencies to prepare for the next phase of America’s econ...Stansberry Research | SponsoredOne tiny company just cracked Google’s $19B problemGoogle’s AI-powered search could cost $20 billion a year in electricity—nearly half its profits. But new resea...True Market Insiders | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredI trusted Trump and got screwedPorter Stansberry says he got one thing wrong—and now millions of Americans could pay the price. After warning...Porter & Company | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eucrates Biomedical Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eucrates Biomedical Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.